NANETS: Despite Dose Reductions, Everolimus Promising in Advanced Pancreatic Neuroendocrine Tumors
Everolimus is a promising treatment option for pancreatic neuroendocrine tumors (pNETs), even though dose reductions are required for most patients.
NANETS 2014 Symposium
NANETS: Intraoperative 5-FU May Reduce Need for Additional Surgeries in Midgut Neuroendocrine Tumors
Intraoperatively-placed 5-fluouracil (5-FU) chemotherapy at lymph node surgical dissection beds may lower the chance of necessary surgery.
NANETS: Pancreatic Neuroendocrine Tumors Harbor DNA Repair Gene Defects
Pancreatic neuroendocrine tumors (pNETs) harbor genetic mutations in DNA repair pathways that represent “strong candidates”.
NANETS: Axitinib Yields “Promising” Progression-Free Survival for Advanced Carcinoid Tumors
Axitinib could be an effective treatment option for unresectable and metastatic carcinoid tumors.
NANETS: Diarrhea Impacts Health-Related Quality of Life in Patients with Neuroendocrine Tumors
Diarrhea is associated with worse health-related quality of life in patients with neuroendocrine tumor (NET) symptoms.
NANETS: Hypermethylation Common in Small Intestinal Neuroendocrine Tumors
Epigenetic signatures may help detect and differentiate small intestinal neuroendocrine tumors (SINETs) from other tumor types.
NANETS: Radical Resection of Pancreatic Neuroendocrine Tumors with Liver Mets Often Prolongs Survival
Poorly differentiated pancreatic neuroendocrine carcinoma (PNEC) grade 3 tumors demonstrate lower survival after radical resection of PNETs.
NANETS: Pancreastatin Predicts Survival in Patients with Neuroendocrine Tumors
Higher pancreastatin associated with worse survival times in surgically treated small bowel (SBNET) and pancreatic neuroendocrine tumors (PNETs).
NANETS: Lymph Node Ratio Predicts Survival in Patients with Gastrointestinal (GI) Carcinoid Neuroendocrine Tumors
Lymph node ratio (LNR) may offer better survival prediction over the current measure for patients with carcinoid neuroendocrine tumors.
Some Locally-Advanced and Metastatic Pulmonary Carcinoid Tumors Respond to Chemotherapy
Octreotide has demonstrated promising results vs. a subset of carcinoid tumors, despite a lower overall response rate.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in NANETS 2014 Symposium
Loading... 
Loading...